The functional GRHL3-filaggrin axis maintains a tumor differentiation potential and influences drug sensitivity
Details
Publication Year 2021-08-04,Volume 29,Issue #8,Page 2571-2582
Journal Title
Molecular Therapy
Publication Type
Research article
Abstract
Current therapies for treating heterogeneous cancers such as head and neck squamous cell carcinoma (HNSCC) are non-selective and are administered independent of response biomarkers. Therapy resistance subsequently emerges, resulting in increased cellular proliferation that is associated with loss of differentiation. Whether a cancer cell differentiation potential can dictate therapy responsiveness is still currently unknown. A multi-omic approach integrating whole-genome and whole-transcriptome sequencing with drug sensitivity was employed in a HNSCC mouse model, primary patients' data, and human cell lines to assess the potential of functional differentiation in predicting therapy response. Interestingly, a subset of HNSCC with effective GRHL3-dependent differentiation was the most sensitive to inhibitors of PI3K/mTOR, c-Myc, and STAT3 signaling. Furthermore, we identified the GRHL3-differentiation target gene Filaggrin (FLG) as a response biomarker and more importantly, stratified HNSCC subsets as treatment resistant based on their FLG mutational profile. The loss of FLG in sensitive HNSCC resulted in a dramatic resistance to targeted therapies while the GRHL3-FLG signature predicted a favorable patient prognosis. This study provides evidence for a functional GRHL3-FLG tumor-specific differentiation axis that regulates targeted therapy response in HNSCC and establishes a rationale for clinical investigation of differentiation-paired targeted therapy in heterogeneous cancers.
Keywords
Animals; Biomarkers, Tumor/*genetics; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins/*genetics; Filaggrin Proteins/*genetics; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms/*genetics; Humans; Mice; Neoplasm Transplantation; Prognosis; Signal Transduction; Squamous Cell Carcinoma of Head and Neck/*genetics; Transcription Factors/*genetics; Exome Sequencing; Whole Genome Sequencing; Filaggrin; Grhl3; Hnscc; Stat3; biomarkers; c-MYC; differentiation; mTOR; sensitivity; targeted therapy
Department(s)
Laboratory Research
PubMed ID
33775911
Open Access at Publisher's Site
https://doi.org/10.1016/j.ymthe.2021.03.016
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2025-05-30 08:01:29
Last Modified: 2025-05-30 08:02:20

© 2025 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙